Edition:
United States

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Select Market

53.22USD
4:00pm EDT
Change (% chg)

$-1.48 (-2.71%)
Prev Close
$54.70
Open
$54.69
Day's High
$55.27
Day's Low
$53.22
Volume
184,649
Avg. Vol
290,522
52-wk High
$67.10
52-wk Low
$15.69

PTLA.OQ

Chart for PTLA.OQ

About

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and... (more)

Overall

Beta: 1.36
Market Cap(Mil.): $3,154.14
Shares Outstanding(Mil.): 57.66
Dividend: --
Yield (%): --

Financials

  PTLA.OQ Industry Sector
P/E (TTM): -- 79.56 32.84
EPS (TTM): -4.55 -- --
ROI: -85.68 2.86 14.86
ROE: -119.49 5.27 16.11

BRIEF-Portola Pharmaceuticals ‍says due date for review of BLA for Andexxa is Feb 2, 2018

* Portola Pharmaceuticals announces Andexxa (Andexanet Alfa) Biologics License Application resubmission accepted for review by U.S. FDA

Aug 15 2017

BRIEF-Portola Pharmaceuticals reports Q2 loss per share of $1.22

* Portola Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

Aug 09 2017

BRIEF-Portola announces resubmission of BLA for Andexxa

* Portola Pharmaceuticals announces resubmission of biologics license application for Andexxa (andexanet alfa)

Aug 03 2017

Portola shares soar after FDA approves clot preventing drug

WASHINGTON The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery.

Jun 23 2017

UPDATE 3-Portola shares soar after FDA approves clot preventing drug

WASHINGTON, June 23 The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery.

Jun 23 2017

U.S. FDA approves Portola blood-thinner to prevent blood clots

June 23 The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc. to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery.

Jun 23 2017

BRIEF-Portola Pharmaceuticals interim data from a phase 2A study evaluating Cerdulatinib

* Interim data from a phase 2A study evaluating Cerdulatinib in patients with relapsed/refractory B-cell malignancies

Jun 15 2017

BRIEF-Portola Pharmaceuticals reports Q1 loss per share $0.74

* Portola Pharmaceuticals reports first quarter 2017 financial results and provides corporate update

May 08 2017

BRIEF-Portola Pharmaceuticals reports Q1 loss per share $0.74

* Portola Pharmaceuticals Inc - collaboration and license revenue $5.1 million versus $8.3 million

May 08 2017

Competitors

Earnings vs. Estimates